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Background: Single wall carbon nanotubes (SWCNTs) are considered promising nanoparticles for industrial and
biomedical applications; however their potential toxicity in several biological systems, including the feto-placental
unit, has been demonstrated. Functionalization of SWCNTs with polyethylene glycol chains (PEG-SWCNTs)
dramatically reduces their toxicity, and for this reason PEG-SWCNTs are candidates for biomedical applications.
However, no data are available on their safety for the developing embryo, in spite of the clinical and social
relevance of this topic. The purpose of this study is therefore to investigate the safety of PEG-SWCNTs for their use
as biomedical carriers in pregnancy.
Methods: For toxicological studies, amino-functionalized PEG-SWCNT were intravenously injected in CD1 pregnant
mice at different doses (range 0.1-30 μg/mouse), in single or multiple administrations. For biodistribution studies,
fluorescently labeled PEG-SWCNTs were obtained by acylation of terminal PEG amino groups with near infrared
emitting fluorochromes (PEG-SWCNT-750) and injected at the dosage of 10 μg/mouse, at either day 5.5 (when the
placenta is still developing) or day 14.5 of gestation (when the maturation of the placenta is complete).
Results: We found no adverse effects both on embryos and dams up to the dose of 10 μg/mouse. At the dose of
30 μg/mouse, occasional teratogenic effects, associated with placental damage, were detected both when
administered as a single bolus (1 out of 10 dams; 1 malformed embryo) or as multiple doses (2 out of 10 dams; 5
malformed embryos). The difference in the prevalence of dams with malformed embryos between the 30 μg
exposed group and controls approached the statistical significance (p = 0.06). Hepatic damage in dams was seen
only in the multiple exposure group (4 out of 10; p = 0.04 when compared with the single exposure group or
controls). PEG-SWCNT-750 reached the conceptus when administered early in pregnancy. At later stages, PEG-
SWCNT-750 were detected in the placenta and the yolk sac, but not in the embryo.
Conclusions: PEG-SWCNTs may cause occasional teratogenic effects in mice beyond a threshold dose. Such effect
might depend on their ability to reach the feto-placenta unit. Although not automatically transferable to humans,
these data should be considered if exposing women during pregnancy.Introduction
Since their discovery, almost 20 years ago, carbon
nanotubes (CNTs), a class of fiber-shaped nanoparticles
(NPs), have been indicated as good candidates for many
applications in industrial and biomedical settings. For such
reason, their biocompatibility has been extensively investi-
gated over the last 10 years, and evidences that CNTs
might have negative effects in biological systems have* Correspondence: campagno@med.uniroma2.it; pietroiu@uniroma2.it
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distribution, and reproduction in any mediumbeen reported both in vitro and in vivo, as recently
reviewed by Shvedova et al. [1]. The main targets of occu-
pational and environmental exposure to CNTs are the
lungs, the skin and the gastro-intestinal tract. Due to their
small size (at least one dimension less than 100 nm),
nanoparticles might cross biological barriers [2], and
CNTs have been demonstrated to reach the brain after be-
ing orally administered, indicating that they can access
protected niches [3]. The finding of serious embryotoxic
effects after single wall CNT (SWCNT) administration to
pregnant mice suggests that the placenta might be crossed
by these NPs [4], although nanoparticles might alsoentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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tions. Studies specifically addressing this issue have not
yet been performed.
In addition to the unintended occupational and envir-
onmental exposure, people may be purposefully exposed
to CNTs, given the ability of this material to carry diag-
nostic and therapeutic probes with high efficiency
[5-10]. For biomedical uses, CNTs are generally chem-
ically modified (functionalized) in order to improve
some physical properties, such as solubility in organic or
aqueous solvents and biological fluids. One of the most
used methods of functionalization is represented by con-
jugation with polyethylene glycol (PEG) [11], and the
absence of acute and chronic adverse effects after intra-
venous administration of single wall CNTs (SWCNTs)
conjugated with PEG (PEG-SWCNTs) in mice has been
reported [12]. However, no data are currently available
on the effects of PEG-SWCNT exposure during preg-
nancy in dams and embryos. This matter is relevant, not
only for the obvious clinical and social implications, but
also in light of the high sensitivity of embryonic tissues
to the toxic effects of CNTs, which induce severeFigure 1 Schematic representation of the experimental design for the
biodistribution. Upper panel: Animals were divided into two groups, A an
10 (10 females) or 30 (10 females) μg/mouse PEG-SWCNTs or PBS (18 fema
PEG-SWCNTs (10 females) or PBS (10 females), at different times of gestatio
tissues, placentas and fetuses were analyzed. Lower panels: For biodistribut
(5 females) or 14.5 dpc (5 females) and isolated organs studied either at 6.5embryo abnormalities at doses having no toxic effects on
maternal organs [4].
In this study, we assessed the possible maternal and
fetal effects of PEG-SWCNTs when administered to
pregnant female mice as a bolus or after repeated ad-
ministrations (Figure 1). In order to clarify if SWCNTs
may cause embryotoxic effects by directly reaching the
feto-placental unit, or indirectly through mother-
mediated mechanisms, we performed biodistribution
studies in early pregnancy, when the placenta is shaping,
and at a later stage, characterized by the presence of a
fully developed placenta (Figure 1).
Results and discussion
Production and characterization of PEG-SWCNTs
Individual (non-aggregated) amino-functionalized PEG-
SWCNTs were fabricated from the processing of commer-
cially available single SWCNTs through a non-covalent
protocol based on the adsorption onto SWCNT sidewalls
of phospholipids modified with PEG chains, carrying
amino groups at their end. Phospholipids bind strongly to
SWCNTs through hydrophobic interactions between theevaluation of PEG-SWCNT embryotoxic potential and
d B. Group A received a single administration of either 0.1 (5 females),
les), at 5.5 dpc; group B received three administrations of 10 μg/mouse
n. Animals were sacrificed at day 15.5 of gestation and maternal
ion studies, PEG-SWCNT-750 were administered either at 5.5 dpc
dpc or 15.5 dpc, respectively.
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ving the hydrophilic PEG chains protruding from the side-
wall [13]. PEG chains improve the steric stability of the
nanoparticles and allow further functionalization [13].
Fluorescent PEG-SWCNTs (PEG-SWCNT-750) were
obtained by capping the PEG chain terminal amino
groups on PEG-SWCNTs with near infrared (NIR)-
emitting fluorochromes (Figure 2A).
PEG-SWCNTs and PEG-SWCNT-Seta750 were dis-
persed in PBS (pH 7.4) and formed a stable dispersion of
individual nanoparticles upon standing for several
months at room temperature [14]. MALDI and elemen-
tal analysis data confirmed the presence of intact 2 kDa-
mw PEG chains decorating nanotube sidewalls and the
absence of impurities, respectively (data not shown).
AFM images showed the presence of individual particles
composed by short PEG-SWCNTs having a narrow dis-
tribution of lengths centered at approximately 90 nm
(Figure 2B and C). Finally, we calculated by using our
published model [15] that the PEG density was about
0.1 mmol per gram of nanotube material, corresponding
to approximately 15 PEG chains per nanotube. Analysis
of possible endotoxin contamination of nanoparticle sus-
pensions revealed a content of 3 × 10-3 EU/ml, that was
highly below the FDA limit of 0.5 EU/ml (not shown).
In vivo effect of PEG-SWCNTs
To investigate possible embryotoxicity of PEGylated
nanotubes, different doses were intra-venously adminis-
tered to pregnant mouse females, either as a single bolus
(range 0.1-30 μg/mouse) or in multiple administrations
(10 μg/mouse each). The intra-venous route was chosen
since PEG-SWCNTs have been developed as putative
molecular carriers for biomedical purposes. For females
undergoing a single injection, nanoparticles were admin-
istered at day 5.5 of gestation (5.5 dpc, group A inFigure 2 Production and characterization of PEG-SWCNTs. A. PEG-SWC
phospholipids modified with PEG chains carrying an amino group at their
terminal amino groups on PEG-SWCNTs with NIR-emitting fluorochrome (S
freshly cleaved mica sample (scan size 2.5 × 2.5 μm). C. PEG-SWCNT lengthFigure 1), when embryos have just implanted, and the
definitive placenta is not yet formed, so that the embryo
is separated from the uterine tissue by a layer of tropho-
blast giant cells and extra-embryonic tissues. Dams were
exposed to 0.1 (5 mice), 10 or 30 μg/mouse (10 mice
each) (Figure 1; group A). For multiple exposures, fe-
males received 3 refracted doses of 10 μg/mouse each
(10 females; group B in Figure 1) and injections were
performed every three other days, starting from 5.5 dpc.
For this group, exposure to PEG-SWCNTs occurred
during different stages of placental development. The
presence of placental and/or fetal abnormalities was
assessed in all groups at day 15.5 of gestation. In parallel,
some key maternal organs, such as liver, lungs, heart,
spleen and kidneys were collected for histological
examination.
Females receiving up to 10 μg/mouse of PEG-
SWCNTs did not carry any abnormal fetus nor displayed
tissue histological alterations. By contrast, at the highest
concentration tested we observed fetal abnormalities in
one in ten dams (1/10) exposed to a single injection of
30 μg/mouse (1 malformed embryo) and in 2 out of 10
dams exposed to the three refracted doses of 10 μg/
mouse each (5 malformed embryos). In both groups
similar fetal malformations were observed, consisting in
delayed development of the paws and head abnormal-
ities. In 4 fetuses out of 6, these malformations were as-
sociated with reduced length (around 1.2-1.3 cm), which
was out of two standard deviations in comparison to our
internal growth reference curves. The main results of
these experiments are summarized in Table 1.
Although no statistically significant difference or trend
was observed when comparing mice exposed to 30 μg as
a single dose with those exposed three times to 10 μg, a
trend toward significance was seen when comparing this
latter group with controls (p = 0.11). Furthermore, whenNT were fabricated by the adsorption onto pristine SWCNTs of
end. PEG-SWCNT-750 were obtained by capping the PEG chain
eta750). B. AAC-mode AFM image of PEG-SWCNTs deposited on
distribution (N = 256).
Table 1 Summary of the main parameters evaluated for the embryotoxicity studies
♀ Mean No. fetuses/female CRL Fetal weight (mg) ♀ with malformed fetuses Total No. of resorptions
CTRL 18 13.7 ± 1.3 1.57 ± 0.15 401 ± 11 0 14
100 ng/mouse 5 12.3 ± 1.3 1.60 ± 0.21 396 ± 9 0 3
10 μg/mouse 10 14.0 ± 0.4 1.57 ± 0.14 412 ± 3 0 7
30 μg/mouse 10 12.9 ± 0.7 1.52 ± 0.12 399 ± 14 1/10 (1 fetus) 8
CTRL 3 × 10 10 12.2 ± 1.0 1.61 ± 0.11 392 ± 15 0 8
3 × 10 μg/mouse 10 12.7 ± 1.8 1.58 ± 0.10 395 ± 17 2/10 (3 + 2 fetuses) 7
♀: number of females analyzed.
CRL: crown rump length.
Figure 3 Macroscopic and microscopic analysis of placentas
and embryos after maternal exposure to PEG-SWCNTs. A. A
Fetus showing abnormal development (left) is compared to one
from a control female (right). B. The placenta nourishing the
abnormal fetus (left) appeared abnormally vascularised and slightly
smaller than the one from the control fetus (right). C-F. Reduced
vascularisation in abnormal placentas (C) compared to normal ones
(D) was demonstrated in Azan-Mallory stained sections; similar
results were obtained by immunostaining, using the anti-CD31
antibody: (E) placentas nourishing abnormal fetuses displayed
reduced CD31 expression, compared to normal tissue (F).
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repeated administrations), the difference with controls
approached the statistical significance (p = 0.06).
From a clinical point of view, such results suggest that
the fractionated administration of a dose causing
embryotoxicity, when given as a bolus, does not decrease
the toxic potential, but may actually increase it, presum-
ably as a consequence of nanoparticle accumulation in
tissues, and/or exposure during different stages of preg-
nancy, when the placental barrier displays different per-
meability [16]. In this respect, the evaluation of repeated
exposures is particularly relevant in pregnancy, due to
the dynamic nature of this physiologic process during
which both the sensitivity of the embryo to xenobiotics,
and the efficiency of the placenta as a biological barrier
change depending on the developmental stage.
Fetal abnormalities were always associated with abnor-
mal placental development (Figure 3A and B) consisting
in a moderate reduction in the size (Figure 3B), accom-
panied by a dramatic reduction in the vascularization of
the labyrinth layer (Figure 3C and D) and in the
expression of the pan-endothelial marker CD31
(Figure 3E and F), thus indicating altered development
and vascularization; similar phenotype has been de-
scribed in several mouse mutant models (e.g., notch sig-
nalling pathway mutants) [17-19], and in placentas after
the administration of non pegylated SWCNTs and silica
and titania nanoparticles [4,20] suggesting that adminis-
tration of nanoparticles early in gestation might interfere
with mechanisms important for placental morphogenesis.
With respect to the organs of dams exposed to a single
administration of PEG-SWCNTs, at all tested doses, no
evident structural alterations were identified in lung,
heart, kidney, spleen and liver (not shown). At contrast,
females undergoing multiple administrations displayed a
non significant increase in spleen weight compared to
controls (0.36 ± 0.04 gr vs 0.33 ± 0.03 gr), and liver alter-
ations characterized by clusters of granulocytes, mono-
cytes and megacaryocytes (Figure 4A, b, d and e),
suggesting the occurrence of extramedullary myelopoiesis
in the liver (4 out of 10 females; p = 0.04 when compared
with the single exposure group). No similar phenotype
Figure 4 Histological analysis of maternal liver after exposure
to PEG-SWCNTs. A. Liver sections from dams exposed to vehicle
only (a, b), 30 μg (c) or to three repeated administrations of 10 μg
each (d) were stained with Hematoxylin and Eosin. In the liver from
animals that received three administrations, areas of extramedullary
hematopoiesis were in some cases evidenced (d). (e) Magnification
of the boxed area in d shows the presence of monocyte and
granulocyte like cells (arrows). B. Histograms show no differences in
the number of apoptotic cells in all liver samples analyzed.
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myelopoiesis is observed during immune responses and in-
flammation [21], it is reasonable to hypothesize that the re-
peated administration of PEG-SWCNTs induced a hepatic
inflammatory response. This observation is in line with
previous data from the literature indicating that the liver is
one of the main organs of nanoparticle accumulation and
damage [22,23]. To further investigate hepatic damage, we
evaluated the presence of apoptotic cells in liver tissues: no
sign of apoptosis was detected in livers collected from
pregnant females exposed to either 30 μg in a single ad-
ministration or to the three repeated administrations of
10 μg each (Figure 4B). Similarly, in the two groups, no al-
terations of biochemical parameters, such as liver enzymes
aspartate aminotransferase and alanine aminotransferase,
blood urea nitrogen, creatinine and lactate dehydrogenase
were recorded (Figure 5).
No other significant differences were observed with re-
spect to the weight of dams and normal fetuses, the
number of pups per litter and the number of resorptions
observed in control and treated females (Table 1). In de-
tails, the maternal body weight gain was almost identical
in exposed and non exposed dams, being less than 1%from gestational day 5.5 to gestational day 8.5; from day
9.5 of pregnancy to 11.5 it approached 10%. On day 12.5
it reached 20% and subsequently, up to 15.5 (the day of
sacrifice) a daily 10% increase was observed. From day
8.5 to day 15.5 the difference in weight gain between ex-
posed and non exposed dams was always less than 1%.
Altogether, these observations suggest that exposure to
PEG-SWCNTs is in general well tolerated by adult tis-
sues, although a mild inflammatory response in the liver
might be observed after repeated administrations. These
results were further confirmed by the absence of any
clinical alterations in the exposed animals compared to
controls, such as food and water consumption, weight
gain and behaviour.
Biodistribution analysis of fluorescently labeled PEG-
SWCNTs
In order to assess if the particles were able to reach the
placenta and the embryo, 5.5 day pregnant females were
injected with either 10 μg/mouse of fluorescently la-
beled PEG-SWCNTs (PEG-SWCNT-750), with the
unconjugated fluorophore (Seta750), or with the vehicle
(PBS). Localization of fluorescence in tissues was stu-
died using the Kodak Image Station In Vivo FX appar-
atus. As expected, in vivo, a bright fluorescence was
localized to the liver of mice injected with PEG-
SWCNT-750 (Figure 6c, upper panel), due to the role of
this organ in cleansing the blood from xenobiotics, in-
cluding nanoparticles [24-26]. In addition, bright fluor-
escence was registered in the neck region, compatible
with the localization of the highly vascularised brown
fat (Figure 6c, upper panel). To rule out the possibility
that the visualized fluorescence might be consequence
of fluorophore detachment, a group of pregnant females
was injected with the Seta750 fluorophore itself. The
body clearance of the fluorophore was very rapid, and
already 10 minutes after the injection, accumulation
was visible mainly in the bladder, reflecting fast renal
excretion (Figure 6b, upper panel). Bladder fluorescence
was also detected in animals exposed to PEG-SWCNT
-750, but only after one hour from the injection, indicat-
ing that also in this case renal excretion was occurring,
although with a slower rate; in these females, fluores-
cence distribution was substantially unchanged up to
4 hrs, while in the group that received the unconjugated
fluorophore after 4 hours fluorescence was localized ex-
clusively to the bladder. Due to the site of injection, ani-
mals often displayed fluorescence in the eyes.
Interestingly, comparison between body distribution of
both PEG-SWCNT-750 and Seta750 in non-pregnant
and pregnant animals showed no substantial differences,
indicating that pregnancy per se does not alter nanopar-
ticle body distribution (Figure 7). After 24 h from the
injection, animals were sacrificed and maternal organs,
Figure 5 Determination of biochemical parameters in maternal blood. Values (mean ± SD) measured in the serum of pregnant females
exposed to either 30 μg/mouse in a single administration or in three repeated administrations of 10 μg each. Aspartate and alanine
aminotransferase (AST and ALT), blood urea nitrogen, creatinine and lactate dehydrogenase (LDH) were evaluated. Reference ranges reported as
horizontal lines, were obtained from mice of the same strain, sex, and age.
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luation. Fluorescence was observed in all organs isolated
from the PEG-SWCNT-750 treated females (Figure 8),
with the exception of the brain (Figure 8A, a),
suggesting that these nanoparticles do not cross the
blood brain barrier, or do that in very little amount,
below the detection limit of our system that is around
0.2-0.5 nM (corresponding to about 25-50 ng/ml). No
fluorescence was detectable in any of the organs isolated
from the Seta750 treated females, further supporting the
fast renal excretion of the non-conjugated fluorophore; a
representative image of the liver is shown in Figure 8B.
Taken together these results indicate that the fluorescence
detected in the PEG-SWCNT-750 treated animals
reflected the presence of the nanoparticles.
With respect to the distribution of PEG-SWCNT-750
to the implantation sites and its localization in the pla-
centa and the embryo, we observed that, when adminis-
tered early in gestation (5.5 dpc), the particles reached
the uterus in detectable amounts and localized in corres-
pondence of every implantation site (Figure 9A arrows).
In contrast, uteri from Seta750 treated females did not
show any fluorescence. Similar results were obtainedwhen PEG-SWCNT-750 were administered at
midgestation (14.5 dpc), when the placenta has been
already completely formed (Figure 9B). Fluorescence lo-
calized to every implantation site, with a brighter signal
corresponding to the mesometrial side of the uterus,
where the placenta is located. Pregnant uteri were dis-
sected, and isolated placentas and fetuses analyzed for
fluorescence (Figure 9C-F). Interestingly, we could de-
tect PEG-SWCNT-750 in all the placentas, both on the
maternal and fetal side (Figure 9C and D), but not in fe-
tuses (Figure 9F). A bright fluorescence was also regis-
tered in the yolk sac (Figure 9E). This observation is in
line with published data showing that gold nanoparticles
may cross both the chorioallantoic placenta and the yolk
sac placenta [27].
In spite of a possible transplacental crossing, we did
not detect fluorescence in the fetus, probably as a conse-
quence of a too high dilution of the particles, below the
detection limit of our system. On the other hand, given
the relatively low concentrations of PEG-SWCNTs used
in the present study, the possibility to identify the very
low fraction possibly crossing the placenta by Transmis-
sion Electron Microscopy is very unlikely, also in
Figure 6 In vivo analysis of the biodistribution of fluorescently labelled PEG-SWCNTs. Panels show recording of fluorescence in mice
injected with PBS (a) Seta750 (b) and PEG-SWCNT-750 (c). No fluorescence was recorded in control mice (a) at any time. Already 10 min after the
injection, animals that received the fluorophore Seta750 alone (b) displayed fluorescence almost exclusively localized in the bladder. High
fluorescence was recorded in liver and brown fat of mice administered with PEG-SWCNT-750 (c); one hour after the injection bladder
accumulation of fluorescence was also visible in this group.
Campagnolo et al. Particle and Fibre Toxicology 2013, 10:21 Page 7 of 13
http://www.particleandfibretoxicology.com/content/10/1/21consideration of the short length, carbonaceous nature
and lack of aggregates. However, it is possible that accu-
mulation of nanoparticles in the placenta might indir-
ectly induce embryonic damage, independently from
transplacental crossing. In support to this hypothesis,
using an in vitro placental model, it has been recently
shown that contact of nanoparticles with trophoblast
cells caused alteration in the underlying embryonic cells,
in the absence of transplacental passage [28].
Although our data refer to mouse placenta, there is
strong suggestion that nanoparticles may cross human
placenta also. In fact, in a human ex vivo model, Wick et al.
[29] clearly showed transplacental passage of polystirene
nanoparticles. This experiment has however time limi-
tations (it may last only few hours) and may beFigure 7 Comparison of in vivo biodistribution of PEG-SWCNT-750 in
shows an almost identical distribution pattern of PEG-SWCNT-750 in pregnperformed only in placentas at term; therefore no infor-
mation may be obtained, for examples, on transplacen-
tal crossing during the very early stages of development
of this organ.
Conclusion
Our data indicate that PEG-SWCNTs might have a mild
embryotoxic effect in exposed mice, since relatively high
doses may cause occasional teratogenic effects after ma-
ternal intravenous exposure. We found embryotoxicity
of PEG-modified carbon nanotubes at a dose of 30 μg/
mouse. This dose is equivalent to an approximate
1.2 mg/kg dose (considering a mouse weight of 25 g) or
an approximate 70 mg dose for a 60 kg pregnant patient.
It is reasonable to suppose that such dose might be usedpregnant and non-pregnant animals. Recording of fluorescence
ant and non pregnant mice.
Figure 8 Biodistribution of PEG-SWCNT-750 in isolated maternal organs. 24 hrs after the injection, maternal organs were collected and
fluorescence recorded. A: with the exception of the brain (a), all organs from animals injected with PEG-SWCNT-750 (right column) displayed
much higher fluorescence than the controls (left column). b: lung; c: heart; d: brown fat; e: thymus; f: pancreas; g: spleen; h: kidney. B:
comparison of fluorescence distribution in liver from dams that were exposed to PBS (a), Seta750 (b) or PEG-SWCNT-750 (c).
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nanotubes in humans.
Due to the interspecies differences, the question if
these nanotoxicological data can be related to humans
arises. The mouse placenta is structurally different from
the human placenta, however considerable similarities
exist between the two species [30]: both placentas are
defined as emochorial, with the maternal blood directly
coming in contact with a layer of syncytiotrophoblast
lining the fetal villi, and placental permeability to some
molecules is similar in both species [31]. In addition,
molecular pathways of mouse placental development are
conserved in humans [30]. These observations suggest
that the mouse can be considered a good model to ob-
tain indications on the teratogenic potential of
nanoparticles, although further studies using human
models (e.g., the ex vivo human placenta model or
in vitro systems) are desirable.
An interesting finding of this study is that exposure to
fractionated doses, given at different stages of pregnancy,
cause mild liver damage in dams and perhaps increase
the teratogenic effects. However, given the relativelylimited size of the exposed female population, further
confirmatory studies are needed to clarify the issue
We also demonstrated that PEG-SWCNTs are able to
reach and damage the placenta, an event associated with
alteration of fetal development. In our experimental
model, we could not detect PEG-SWCNTs in fetal tis-
sues; however evidence of their presence in the fetal
compartment of the placenta and the yolk sac suggests
that a contact with the fetus might occur under appro-
priate circumstances.
In light of all the above reported considerations, PEG-




Commercially available SWCNTs were purchased from
Carbon Solution Inc. (Riverside, CA). They were purified
by air oxidation. Amino-functionalized PEGylated
SWCNTs (PEG-SWCNT) were fabricated through our
published non-covalent protocol [15] based on the ad-
sorption of PEG-modified phospholipids onto SWCNTs’
Figure 9 Analysis of the biodistribution of PEG-SWCNT-750 in the uterus, placenta, fetus and fetal membranes. A: at 6.5 dpc isolated
uteri from dams exposed at 5.5 dpc to PEG-SWCNT-750 showed fluorescence in correspondence of the implanted embryos (c, arrows). No
fluorescence was recorded in uteri collected from females exposed to either PBS or Seta750 (a and b, respectively). B: fluorescence recorded in
uteri collected from dams at 15.5 dpc that were either exposed to PBS (left) or PEG-SWCNT-750 (right) at day 14.5 of gestation. C and D: 15.5 dpc
isolated placentas from mice administered with PBS (left) or PEG-SWCNT-750 (right) with maternal (C) or fetal (D) side facing up. E and F: 15.5 dpc
fetal membranes (E) and fetuses (F) from PBS (left) or PEG-SWCNT-750 (right) treated dams.
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SWCNTs (Carbon Solutions, Riverside, CA) were oven
dried at 160°C for 3 h, sonicated with 25 mg of phospho-
lipids modified with amino-functionalized 2-kDa mo-
lecular weight (mw) linear PEG chains (DSPE-PEG(2 k)-
NH2, Avanti Polar Lipids, Alabaster, AL) in PBS for 6 h
in an ultrasonic bath (Ultrasonic Cleaner, Cole-Parmer,
Vernon Hills, IL) and ultracentrifuged (Optima™ XL-80
K Ultracentrifuge, Beckman, Palo Alto, CA) at 20,000 × g
for 6 h at 4°C. Approximately 80% of the supernatant
fraction was collected and ultracentrifuged at 40,000 × g
for 6 h at 4°C. Approximately 80% of this second super-
natant fraction was collected and ultracentrifuged at
70,000 × g for 6 h at 4°C. The resulting pellet was dis-
persed in PBS and filtered through 100 kDa mw-cut off
centrifugal devices (Vivaspin 500, Sartorius, Göttingen,
Germany) to remove free phospholipids. All thefabrication steps were carried out under conditions of
sterility. To carry out investigations about the accumula-
tion profile of PEG-SWCNTs in living animals, fluores-
cent PEG-SWCNTs (PEG-SWCNT-750) were obtained
by acylation of terminal PEG amino groups with N-
hydroxysuccinimide ester (NHS)-modified near infrared
(NIR)-emitting fluorochromes (Seta750-NHS, SETA Bio-
Medicals, Urbana, IL). The fluorochrome had excitation
and emission distribution maxima at 751 nm and
779 nm (in PBS, pH 7.4), respectively, and it was chosen
in order to minimize the background noise arising from
tissue auto-fluorescence.
PEG-SWCNTs were characterized through elemental
analysis, atomic force microscopy (AFM) and matrix-
assisted laser desorption/ionization (MALDI). Elemental
analysis was performed on a samples containing 100 μg/
ml of nanoparticles by Elemental Analysis Inc.
Campagnolo et al. Particle and Fibre Toxicology 2013, 10:21 Page 10 of 13
http://www.particleandfibretoxicology.com/content/10/1/21(Lexington, KY) utilizing Proton Induced X-ray Emission
(PIXE). In PEG-SWCNT samples the amount of metallic
contaminants was under the detection limit of the tech-
nique (0.001 μg/cm2). Samples for AFM imaging were
prepared as follow: first 10 μL of PEG-SWCNTs in PBS
(concentration 2.5 μg/ml) were dropped onto a freshly
cleaved mica substrate (Ted Pella, Redding, CA), next
the droplet was allowed to stand for a couple of minutes
at room temperature, and finally the mica surface was
rinsed with water and dried under a gentle nitrogen
stream. AFM images were recorded using a 5500 AFM
(Agilent Technologies, Santa Clara, CA) in acoustic al-
ternate current (AAC) mode. MALDI samples were pre-
pared as follow: 1 μL of PEG-SWCNTs in PBS diluted
1:1 with matrix solution [10 mg/mL α-cyano-4-
hydroxycinnamic acid in 50% (v/v) acetonitrile/0.1% (v/
v) trifluoroacetic acid/50% (v/v) water] was dropped
onto MALDI plate and allowed to dry at room
temperature. MALDI spectra were recorded by means of
an Autoflex™ II TOF/TOF (Bruker Daltonics Inc.,
Billerica, MA).Dispersion and stability of PEG-SWCNTs
PEG-SWCNTs and PEG-SWCNT-Seta750 were dis-
persed in PBS (pH7.4) at room temperature (approxi-
mately 23°C). Stability of the suspensions was
investigated by recording the UV–vis absorbance
spectrum at various storage times. Both PEG-SWCNT
and PEG-SWCNT-Seta750 freshly fabricated dispersions
(150 μg/ml) showed UV–vis absorbance spectra charac-
terized by distinct and sharp peaks corresponding to the
van Hove singularity transitions; thus suggesting the
presence of individually dispersed nanoparticles [14].
The UV–vis spectra did not display any changes upon
storing nanotube solutions for several months at room
temperature in PBS, thus suggesting absence of
aggregation.
For animal exposure experiments, PEG-SWCNT solu-
tions that were not older than 1 month were used. The
UV–vis absorbance spectrum of nanotube solutions was
regularly checked before their use in order to confirm
that they were formed by individual (not-aggregated)
nanoparticles. Stability of the fluorescent tag (Seta750)
conjugated to PEG-SWCNT-750 was also investigated.
PEG-SWCNT-750 solution was stored for two weeks at
room temperature in PBS, filtered once through
100 kDa-mw cut-off centrifugal filtering devices and the
UV–vis absorbance spectrum of the eluate recorded.
The latter showed a very faint peak centred at approxi-
mately 750 nm, thus suggesting that the release of the
fluorescent tag from PEG-SWCNT-750 was minimal.
For the determination of endotoxin content of PEG-
SWCNT samples, the LAL Chromogenic EndotoxinQuantitation kit (Thermo Scientific, Rockford, IL, USA)
was used.
Animal model
In the present study pregnant and non-pregnant females
of the CD1 strain were used; such outbred strain is con-
sidered a multipurpose model suitable for toxicological
studies. Animals were housed and mated under standard
laboratory conditions and treated using humane care in
order to inflict the least possible pain. All experiments
were approved by the Institutional Animal Care and Use
Committee (IACUC) and carried out according to the
Italian and European rules (D.L.vo 116/92; C.E. 609/86;
European Directive 2010/63/EU). A veterinary surgeon
has been present during the injection and blood sample
collection experiments. Animal handling, before and
after experiment, has been carried out only by trained
personnel.
In vivo analysis of fluorescently labeled PEGylated-SWCNT
biodistribution
For the evaluation of nanoparticle distribution in mater-
nal organs, placentas and fetuses, mice were adminis-
tered with fluorescently labeled PEG-SWCNTs (PEG-
SWCNT-750; 5 animals), or with the fluorochrome
Seta750 only (5 females), at the same concentration as
that conjugated to the nanotubes. The concentration of
free Seta 750 in PBS was calculated by recording the ab-
sorbance spectrum of Seta750 in PBS and dividing the
value of absorbance at 750 nm by the extinction coeffi-
cient furnished by the supplier. The concentration of
Seta750 bound to the nanotubes was calculated by a
two-step process. First, the absorbance spectrum of
Seta750 bound to the nanotubes was calculated by
subtracting the absorbance spectrum of fluorochrome-
devoid nanotubes from the spectrum of nanotubes
loaded with fluorochromes. Next, the obtained value of
absorbance at 750 nm was divided by the extinction co-
efficient furnished by the supplier. Control animals (5
animals) received the same volume of the dispersant
medium (PBS). Animals were intra-venously injected
with 10 μg of nanoparticles in a volume of 100 μl at ei-
ther day 5.5 or day 14.5 of gestation, via the retro-bulbar
plexus, as previously reported [4]. Such route of admin-
istration is considered an alternative to the tail vein in-
jection and is recommended for small laboratory
animals [32], since it is much less technically challen-
ging, does not require warming preparation of the ani-
mal or anesthesia, and the whole procedure is only a
matter of seconds. For nanoparticle administration, the
mouse was immobilized on absorbent paper, keeping it
motionless, and a volume of 100 μl was gently injected
in the center of the retro-orbital sinus of the right eye,
by using a 1 cc syringe equipped with a 27 gauge needle.
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local edema or relevant bleeding, were ever observed.
Biodistribution of fluorescence was analyzed using a
Kodak Image Station In Vivo FX apparatus after 10 mi-
nutes (time 0), 1 hour (time 1) and 4 hours (time 2). In
order to determine the detection limit of our system, we
have evaluated fluorescence of PEG-SWCNT-750 sam-
ples of scalar concentrations and observed no fluores-
cence between 25 and 50 ng/ml. For comparing tissue
distribution between pregnant and non pregnant ani-
mals, non-pregnant females were also exposed to
nanoparticles. Recording of the fluorescence was
obtained during anesthesia, (Avertin 250 mg/kg) with
the animals lying in the prone and supine position.
Anesthesia lasted up to about 4 hr, that was the duration
of fluorescence recording in live animals. After recover-
ing from anesthesia, animals were placed back in their
cages. After 24 hr, animals were euthanized and immedi-
ately placed in the Kodak apparatus for further evalu-
ation of fluorescence distribution. Maternal organs,
placentas and fetuses were then isolated and their fluor-
escence recorded.Evaluation of PEG-SWCNT embryotoxic potential
PEGylate-SWCNTs were intravenously administered to
pregnant females as above reported. Briefly, six to eight
week old CD1 females were used. The mean age in all
groups ranged from 6.8 to 7.2 weeks. For mating, 2-3 fe-
males were distributed in each cage containing one male
of proven fertility. For each experiment, 5 females were
randomly allocated to the different exposure groups,
each of which had a predetermined final size of at least
5 animals. The presence of a vaginal plug was checked
every morning, and the day of the vaginal plug was con-
sidered day 0.5 of gestation.
Pregnant females were divided in two groups, depend-
ing on the type of analysis intended: group A received
either PEGylate-SWCNTs or vehicle on day 5.5 of gesta-
tion (5.5 dpc). For this group, administered doses were
either 0.1 (5 females), 10 (10 females) or 30 μg/mouse
(10 females, Table 1 and Figure 1). Group B was admin-
istered with a total amount of nanoparticles of 30 μg/
mouse (10 females), but in three refracted doses of
10 μg/mouse, on day 5.5, 8.5 and 11.5 of gestation. In
this case, intra venous administration was performed al-
ternating injections in the right and left retro-orbital
plexus, so that administration through the same eye oc-
curred after six days. Control animals (18 for single ad-
ministration and 10 for repeated injections) were
administered with the PBS, that was the medium in
which nanoparticles were dispersed. No local complica-
tions secondary to the injection procedure were
observed.The doses of PEG-SWCNTs used in this study are in
the lower range of those employed in in vivo studies,
showing no toxic effect in adult animals [12].
All groups were sacrificed at 15.5 dpc using carbon di-
oxide, and their organs, placentas and fetuses collected
for further analyses. Maternal organs from all animals,
including liver, lung, kidney and spleen were fixed and
processed for paraffin embedding. Spleens were
weighted before fixation. Placentas and fetuses were
carefully evaluated for the presence of malformations
under a stereomicroscope. Fetuses that presented evi-
dent morphological abnormalities were photographed
and then fixed with their placentas in 4% paraformalde-
hyde together with a morphologically normal sibling for
subsequent histochemical and immuno-histochemical
analysis. In parallel, fetuses and placentas from control
mothers, which received the vehicle itself, were
analyzed.
Biochemical analysis of maternal blood
All blood samples were collected by retro-orbital bleed-
ing in SST microtainers (Serum Separator Tube, Becton,
Dickinson and Company, USA), from animals anesthe-
tized with a drop of local anesthetic (Novesina, Novartis
Pharma S.p.A., Italy). All samples were centrifuged in a
microcentrifuge (5415R model, Eppendorf s.r.l., Italy) at
13,000 rpm for 7 min to separate the serum. Serum
levels of aspartate aminotransferase, alanine aminotrans-
ferase, creatinine, blood urea nitrogen and lactate de-
hydrogenase were measured using the automatic
analyzer Keylab (BPC BioSed s.r.l., Rome, Italy).
Histochemical and immuno-histochemical analysis of
maternal tissues
For histochemical analysis, tissues from all animals used
in this study were collected, and processed for paraffin
embedding. At least twenty sections (one every other 10)
of each paraffin block have been routinely stained by
H&E. Based on results of the H&E staining, selected
paraffin blocks were used for immuno-histochemical
analysis. Five micron sections were collected on slides
and a part was stained with hematoxylin and eosin, a
part used for immuno-histochemical analysis with the
rat monoclonal antibody anti-CD31 (clone Mec13.3, BD
Pharmingen, NJ, USA). Briefly, slides were de-
paraffinized in xylene, rehydrated through the ethanol
series and treated in 0.3% H2O2-methanol for 30 min at
room temperature (RT) to block endogenous peroxidase
activity. Following a 30 min pre-treatment at 37°C with
30 μg/ml proteinase K (in 0.2 M Tris–HCl, pH 7.2), each
section was incubated with a blocking reagent (0.5%,
TSA-Indirect Kit, NEN Life Sciences) for 30 min at RT,
and finally incubated overnight at 4°C with the anti-
CD31 antibody at a concentration of 2.5 μg/ml. For
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non-specific rat IgG at the same concentration as the
primary antibody. After 30 min incubation with second-
ary biotinylated anti-rat antibodies, staining was revealed
using the Tyramide Amplification System (TSA-Indirect
Kit, NEN Life Sciences). Slides were counterstained with
Mayer’s hematoxylin for 5 min, dehydrated and mounted
in Permount mounting medium.
Apoptosis was evaluated with the In Situ Cell Death
Detection Kit from Roche (Roche Applied Science, IN,
USA), following the manufacturer specifications.
Statistical analysis
When not otherwise stated, data are presented as mean ±
standard error. A two-tailed value of P < 0.05 was consid-
ered statistically significant. Student’s t test was used for
inter-group comparison of continuous variables (e.g.
weight of dams and fetuses, number of resorptions, fetal
size), whereas Fisher’s exact text was used for comparison
of categorical variables (e.g. prevalence of dams with at
least one malformed embryo, prevalence of malformed
embryos, prevalence of liver damage). Analyses were
performed by means of the software SPSS Statistics 19
(IBM Corporation, Armonk, NY).
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